Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.55 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 6/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.50 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1744994 | 0.86 | CYP4F2 (0.59) | CYP4F2CYP4A11LTA4HLMNAL3MBTL1 | |
| SCHEMBL30257467 | 0.85 | LTA4H (0.56) | LTA4HBRD4CYSLTR2CYSLTR1 | |
| SCHEMBL12549253 | 0.85 | LTA4H (0.59) | LTA4HLMNAALDH1A1BRD4CYSLTR2 | |
| SCHEMBL26455103 | 0.85 | LMNA (0.66) | LMNAL3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL1667461 | 0.84 | PLA2G4A (0.58) | LTA4HLMNAL3MBTL1ALDH1A1MEN1 | |
| SCHEMBL8000090 | 0.84 | LTA4H (0.57) | CYP4F2CYP4A11LTA4HLMNAL3MBTL1 | |
| SCHEMBL28538108 | 0.84 | CYP4F2 (0.60) | CYP4F2CYP4A11LTA4HLMNAL3MBTL1 | |
| SCHEMBL10726761 | 0.84 | LTA4H (0.57) | LTA4HBRD4CYSLTR2CYSLTR1 | |
| SCHEMBL2886166 | 0.84 | LTA4H (0.57) | CYP4F2CYP4A11LTA4HBRD4CYSLTR2 | |
| SCHEMBL7279461 | 0.83 | CYP4F2 (0.59) | CYP4F2CYP4A11LTA4HLMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1657235-B1 | Phenethanolamine-derived haptens, immunogens and conjugates comprising them and antibodies recognising said immunogenes and conjugates | RANDOX LAB LTD (GB) | 2011-09-21 | — | — | EP | disclosed |
| US-7192722-B2 | Phenethanolamine-derived haptens, immunogens, antibodies and conjugates | RANDOX LABORATORIES (GB) | 2007-03-20 | — | — | US | disclosed |
| US-7192722-B2 | Phenethanolamine-derived haptens, immunogens, antibodies and conjugates | RANDOX LABORATORIES (GB) | 2007-03-20 | — | — | US | disclosed |
| US-20060223132-A1 | uses in competitive immunoassays for the detection of ractopamine, isoxsuprine and ritodrine | RANDOX LABORATORIES LIMITED (GB) | 2006-10-05 | — | — | US | disclosed |
| EP-1657235-A2 | Phenethanolamine-derived haptens, immunogens and conjugates comprising them and antibodies recognising said immunogenes and conjugates | Randox Laboratories Ltd. (GB) | 2006-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223132-A1 | uses in competitive immunoassays for the detection of ractopamine, isoxsuprine and ritodrine | HRH3, HRH4, HRH1 | CYP4F2 514/4885CYP4A11 1107/4885LTA4H 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.